Download presentation
Presentation is loading. Please wait.
Published byEvelyn Kirton Modified over 9 years ago
1
Guillermo Rocha W Bruce Jackson Marginal Ulcers or Peripheral Ulcerative Keratitis
2
In this interactive module, peripheral ulcerative keratitis will be reviewed. This will be in the context of a diagnostic classification, management algorithm and case presentations. Learning Objectives 2 To better understand the various etiologies of corneal ulcers including Infectious vs. Non-Infectious and Systemic vs Local Discuss the approach to diagnosis including dry eye testing, review of systems, cultures and systemic testing Review management principles including wound healing, prevention of perforation and addressing the underlying condition
3
Crescent shaped, destructive inflammatory lesion affecting the juxtalimbal corneal tissue Often associated with systemic disease May signify “vasculitis” and thus, be potentially life-threatening Peripheral Ulcerative Keratitis (PUK) 3 Rowe JA, Barney NP. Principles and Practice of Cornea, Ch 32; Copeland, Afshari, Eds.
4
4 These are all PUK – How do you manage them?
5
MARGINAL INFILTRATIVE / ULCERATIVE KERATITIS 5 Bacteria and Fungi Viruses Acanthamoeba Systemic Autoimmune/ Inflammatory Local Toxic Infectious Sterile Etiology
6
6 12 34 56 What would you use? No therapy Antibiotics Steroids Antifungals Antihistamines Systemic drugs
7
TWO CASES TO CONSIDER 7
8
8 What would you do?
9
History The patient Previous therapies KNOW MORE ABOUT… 9
10
10 What would you do?
11
Enhance wound healing Prevent perforation Address the underlying condition MANAGEMENT PRINCIPLES 11
12
ETIOLOGIC CONSIDERATIONS 12
13
13 Which is which?
14
14 Which is which?
15
NON INFECTIOUS PERIPHERAL INFILTRATIVE KERATITIS 15 Stern GA. Cornea, Ch 23; Krachmer, Mannis, Holland, Eds. Microulcerative Macroulcerative
16
Generally manifestation of systemic, immune- mediated disease Most common: Rheumatoid arthritis, Wegener’s granulomatosis and polyarteritis nodosa NON INFECTIOUS PERIPHERAL INFILTRATIVE KERATITIS Stern GA. Cornea, Ch 23; Krachmer, Mannis, Holland, Eds. 16 Microulcerative Macroulcerative Punctate marginal keratitis Peripheral keratitis associated with blepharitis
17
NON INFECTIOUS PERIPHERAL INFILTRATIVE KERATITIS 17 Stern GA. Cornea, Ch 23; Krachmer, Mannis, Holland, Eds. Microulcerative Punctate marginal keratitis –Staphylococci, Streptococci, Haemophilus, hypersensitivity to medications Peripheral keratitis associated with blepharitis –Catarrhal ulceration –Phlyctenulosis –Peripheral rosacea keratitis
18
Size Number Location Intervening space …not really, although: –Catarrhal may have intervening space, and be located at the 2, 4, 8 and 10 o’clock positions Are There Any Distinguishing Features? 18
19
PERIPHERAL CORNEAL INFLAMMATION Stern GA. Cornea, Ch 23; Krachmer, Mannis, Holland, Eds. 19
20
Treat without testing? Treat, but testing required? Which Ones Need to Be Worked Up? 20
21
Avoid treating with topical steroids HERPETIC ULCERS (HSV) 21
22
CONSIDER THE ROLE OF: 22
23
Dry Eye Questionnaire Assessment of lid margins Tear film breakup time Corneal and conjunctival staining Tear osmolarity Schirmer test Serology: SSA, SSB, Rheumatoid Factor, ANA DRY EYE TESTING 23 BACK TO SLIDE 78 BACK TO SLIDE 78 BACK TO SLIDE 97 BACK TO SLIDE 97
24
Bacterial Viral Fungal Acanthamoeba Chalmydia CULTURES 24 BACK TO SLIDE 78 BACK TO SLIDE 78 BACK TO SLIDE 97 BACK TO SLIDE 97
25
Rule out those conditions associated with peripheral ulcerative keratitis REVIEW OF SYSTEMS 25 BACK TO SLIDE 78 BACK TO SLIDE 78 BACK TO SLIDE 97 BACK TO SLIDE 97
26
Complete blood count Erythrocyte sedimentation rate C reactive protein Urinalysis Chest X-ray Renal function tests Syphilis, Hepatitis C SYSTEMIC TESTING 26 BACK TO SLIDE 78 BACK TO SLIDE 78 BACK TO SLIDE 97 BACK TO SLIDE 97
27
Rheumatoid factor Antinuclear antibodies Antineutrophil cytoplasmic antibodies (ANCA) Tissue biopsy –Lung, kidney SYSTEMIC TESTING 27 BACK TO SLIDE 78 BACK TO SLIDE 78 BACK TO SLIDE 97 BACK TO SLIDE 97
28
MARGINAL INFILTRATE 28 When to culture? When to use antibiotics? When to add steroids?
29
ETIOLOGIC CONSIDERATIONS 29
30
ETIOLOGIC CONSIDERATIONS 30 Catarrhal infiltrates Phlyctenulosis Acne rosacea Psoriasis Contact lenses Topical anesthetic abuse Toxic Food allergies Mooren’s ulcer (??)
31
31
32
32
33
33
34
ETIOLOGIC CONSIDERATIONS 34
35
ETIOLOGIC CONSIDERATIONS 35 Bacterial Viral Fungal Acanthamoeba
36
36
37
37
38
One infiltrate Larger than 2mm in diameter Less than 3mm from the visual axis ALWAYS CULTURE 1-2-3 RULE 38
39
39
40
History of contact lens wear or trauma Non resolving Ring infiltrate ALWAYS CULTURE CONSIDER CORNEAL BIOPSY ALSO… 40
41
ETIOLOGIC CONSIDERATIONS 41
42
ETIOLOGIC CONSIDERATIONS 42 Herpes virus Chlamydia
43
43
44
44
45
ETIOLOGIC CONSIDERATIONS 45
46
ETIOLOGIC CONSIDERATIONS 46 Rheumatoid arthritis SLE Discoid lupus Scleroderma Relapsing polychondritis Crohn’s Ulcerative colitis Polyarteritis nodosa Wegener’s granulomatosis Churg-Strauss Benign hypergammaglobulinemic purpura Temporal arteritis
47
47
48
48
49
49
50
50
51
51
52
52
53
53
54
54
55
55
56
56
57
57
58
58
59
59
60
60
61
Enhance wound healing Prevent perforation Address the underlying condition MANAGEMENT PRINCIPLES 61
62
62 ENHANCE WOUND HEALING
63
Lid Hygiene Antibiotic coverage Lubrication: Preservative-free Autologous serum drops ENHANCE WOUND HEALING 63
64
64 PREVENT PERFORATION
65
Collagenase or collagenase synthetase inhibitors –1% Medroxyprogesterone –10-20% Acetylcysteine Cyclosporine 0.05% Doxycycline Tissue adhesive, bandage CL, lamellar and tectonic grafts, amniotic membrane transplant CAUTION: topical steroids PREVENT PERFORATION 65
66
66 ADDRESS THE UNDERLYING CONDITION
67
Glucocorticoids –IV pulse initially –Oral Systemic immunomodulators –Antimetabolites –Alkylating agents –T cell inhibitors –Biologics ADDRESS THE UNDERLYING CONDITION 67
68
Glucocorticoids –IV pulse initially: 1g per day, for 3 consecutive days –Oral: 1mg/kg/day, not to exceed 60-80 mg/day ADDRESS THE UNDERLYING CONDITION 68
69
Systemic immunomodulators –Antimetabolites: MTX, AZT, Mycophenolate mofetil, Leflunomide –Alkylating agents: Cyclophosphamide –T cell inhibitors: Cyclosporin A –Biologics: Infliximab, etanercept, rituximab ADDRESS THE UNDERLYING CONDITION 69
70
Back to Our Two Cases to Consider 70
71
71 What would you do?
72
History The patient Previous therapies KNOW MORE ABOUT… 72
73
62yoM Original presentation: conj cyst OD -marsupialization MGD = full Lid Hygiene, tea tree oil facewash, Doxycycline Possible history of CRVO? Amblyopia? 5 mo later: PUK CASE HISTORY SH 73
74
CASE HISTORY SH 74
75
CASE HISTORY SH 75
76
CASE HISTORY SH 76
77
CASE HISTORY SH 77
78
What would you do? 78 Do you think this is Dry Eye/Ocular Surface related? Do you think this is a local infection? Do you think this is related to a systemic condition? Do you think systemic testing is warranted?
79
62yoM Original presentation: conj cyst OD -marsupialization MGD = full Lid Hyg, TTO, Doxy Possible history of CRVO? Amblyopia? 5 mo later: PUK Prednisolone acetate 1% tid –better 3 wks later Tests: all negative, except atypical ANCA CASE HISTORY SH 79
80
CASE HISTORY SH: 3 WEEKS LATER 80
81
Worse again: 20/60 New lesions superiorly and inferiorly What would you do? ONE MONTH LATER… 81
82
Enhance wound healing –Lid hygiene –Fucidic acid to lids Prevent perforation –Prednisolone acetate 1% –Doxycycline 100mg PO qhs Address the underlying condition –Systemic testing: Atypical ANCA (+) –Referral to Internal Medicine MANAGEMENT HISTORY 82
83
IMPROVED AND STABLE 83
84
IMPROVED AND STABLE 84
85
WHAT ABOUT ANCA? 85
86
Antineutrophil cytoplasmic antibodies are specific and sensitive markers for different forms of vasculitides ANCA 86
87
87
88
51yoF Glaucoma on multiple meds Chronic red eye OS 1-2 yrs Is this toxic? Stopped everything Some improvement, but… 4-5mo later, worse, gooey, leaky, on Pataday Now with PUK OD perfectly fine CASE HISTORY FW 88
89
CASE HISTORY FW: 5MO 89
90
CASE HISTORY FW: 5MO 90
91
CASE HISTORY FW: 5MO 91
92
CASE HISTORY FW: 5MO 92
93
CASE HISTORY FW: 5MO 93
94
CASE HISTORY FW: 8MO 94
95
CASE HISTORY FW: 8MO 95
96
CASE HISTORY FW: 8MO 96
97
What would you do? 97 Do you think this is Dry Eye/Ocular Surface related? Do you think this is a local infection? Do you think this is related to a systemic condition? Do you think systemic testing is warranted?
98
51yoF Glaucoma on multiple meds Chronic red eye OS 1-2 yrs Toxic? Stopped everything 4-5mo later, worse, gooey, leaky, on Pataday PUK Cultures: –Dx Strep Anginosus, Eikenella corrodens –Sensitive to Ciprofloxacin –Improved! CASE HISTORY FW 98
99
CASE HISTORY FW: Follow Up –on Ciprofloxacin gtt/ung 99
100
CASE HISTORY FW: Follow Up –on Ciprofloxacin gtt/ung 100
101
CASE HISTORY FW: Follow Up –on Ciprofloxacin gtt/ung 101
102
CASE HISTORY FW: Follow Up –on Ciprofloxacin gtt/ung 102
103
Worse again! Marked inflammation, PUK, discharge, corneal thinning and vascularization Extreme photophobia NO intraocular inflammation BUT… 2 MO LATER 103
104
104 What would you do?
105
Enhance wound healing –Lid hygiene –Continue with topical ciprofloxacin Prevent perforation –IV Methylpredisolone 1g daily for 3 days –Continue with oral Prednisone Address the underlying condition –Referral to Internal Medicine: IMT Improved at last visit MANAGEMENT HISTORY 105
106
LATEST FOLLOW-UP 106
107
LATEST FOLLOW-UP 107 Well controlled on oral Prednisone and Methotrexate
108
ETIOLOGIC CONSIDERATIONS DIAGNOSTIC CONSIDERATIONS MANAGEMENT PRINCIPLES SUMMARY 108
109
ETIOLOGIC CONSIDERATIONS 109
110
DIAGNOSTIC CONSIDERATIONS: 110
111
MANAGEMENT PRINCIPLES: 111
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.